References
- Liu B, Rao Q, Zhu Y, et al. Metaplastic thymoma of the mediastinum. A clinicopathologic, immunohistochemical, and genetic analysis. Am J Clin Pathol. 2012;137(2):1–7. doi: 10.1309/AJCP0T1JFYLMPHMI.
- Travis WB, Burke AP, Marx A, et al. WHO classification of tumors of the lung, pleura, thymus and heart. 4th ed. Lyon: IRAC; 2015.
- Zhao J, Zhao R, Xiang C, et al. YAP1–MAML2 fusion as a diagnostic biomarker for metaplastic thymoma. Front Oncol. 2021;11:692283. doi: 10.3389/fonc.2021.692283.
- Wells K, Lamrca A, Papaxoinis G, et al. Unique correlation between GTF2I mutation and spindle cell morphology in thymomas (type A and AB thymomas). J Clin Pathol. 2023;76(7):463–466. doi: 10.1136/jclinpath-2021-207837.
- Vivero M, Davineni P, Nardi V, et al. Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1–MAML2 gene fusions. Mod Pathol. 2020;33(4):560–565. doi: 10.1038/s41379-019-0382-x.
- Liu Y, Wu S, Zhou L, et al. Pitfalls in RET fusion detection using break-apart FISH probes in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2021;106(4):1129–1138.
- Georgiev A, Hilendarov A, Tsvetkova S, et al. Thymoma type B2 progression, due to fear of contamination, in association with hydrocephalus: a case report of avoidant behavior during COVID-19 pandemic. Radiol Case Rep. 2022;17(3):680–684. doi: 10.1016/j.radcr.2021.12.028.
- Kang G, Yoon N, Han J, et al. Metaplastic thymoma: report of 4 cases. Korean J Pathol. 2012;46(1):92–95. doi: 10.4132/KoreanJPathol.2012.46.1.92.
- Tajima S, Yanagiya M, Sato M, et al. Metaplastic thymoma with myasthenia gravis presumably caused by an accumulation of intratumoral immature T cells: a case report. Int J Clin Exp Pathol. 2015;8(11):15375–15380.
- Poorabdollah M, Mehdizadeh E, Mohammadi F, et al. Metaplastic thymoma: report of an unusual thymic epithelial neoplasm arising in the wall of a thymic cyst. Int J Surg Pathol. 2009;17(1):51–54. doi: 10.1177/1066896908315754.
- Marx A, Belharazem D, Lee DH, et al. Molecular pathology of thymomas: implications for diagnosis and therapy. Virchows Arch. 2021;478(1):101–110. doi: 10.1007/s00428-021-03068-8.
- Sekine S, Kiyono T, Ryo E, et al. Recurrent YAP1–MAML2 and YAP1–NUTM1 fusions in poroma and porocarcinoma. J Clin Invest. 2019;129(9):3827–3832. doi: 10.1172/JCI126185.
- Picco G, Chen ED, Alonso LG, et al. Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR–Cas9 screening. Nat Commun. 2019;10(1):2198. doi: 10.1038/s41467-019-09940-1.
- Guo Q, Quan MY, Xu L, et al. Enhanced nuclear localization of YAP1-2 contributes to EGF-induced EMT in NSCLC. J Cell Mol Med. 2022;26(4):1013–1023. doi: 10.1111/jcmm.17150.
- Shao DD, Xue W, Krall EB, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014;158(1):171–184. doi: 10.1016/j.cell.2014.06.004.